Company / Operating Income per Share
Avalo Therapeutics, Inc. Operating Income per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$6.96
FY2025
5-year range
-$696.06 / -$1.10
FY2021-FY2025
Trend
+91.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income per Share has fluctuated over the past 9 years, ranging from $-696.06 in FY2023 to $1.47 in FY2017.
Based on SEC 10-K filings.
-6.96 in FY2025.
Improved from $-696.06 to $-6.96 over the past 2 years.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income per share increased 91.9% year-over-year.
- Peak operating income per share was recorded in FY2017.
- Lowest operating income per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.96 | +91.9% |
| FY2024 | -$85.45 | +87.7% |
| FY2023 | -$696.06 | -17375.0% |
| FY2022 | -$3.98 | -263.7% |
| FY2021 | -$1.10 | +33.3% |
| FY2020 | -$1.64 | -315.0% |
| FY2019 | -$0.40 | +65.0% |
| FY2018 | -$1.13 | -176.9% |
| FY2017 | $1.47 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026